Stimulus Plans For Japan's Life Sciences Industries May Not Address Main Challenge - Bio Japan Conference
This article was originally published in PharmAsia News
Executive Summary
YOKOHAMA, Japan - Government agencies will initiate a plan in June 2011 to jumpstart Japan's lagging bioventure market, but government officials seem wary about being able to transform Japan's venture culture, a necessity for funding Japan's innovative technologies and medicines
You may also be interested in...
Daiichi Sankyo Withdraws Shipment Of Half The Company's Entire Influenza Vaccine Supply
TOKYO - Daiichi Sankyo Co. Ltd. will trash nearly half of its annual influenza vaccines after tests revealed batches were contaminated by avian reovirus. The company's joint venture with Kitasato Institute for vaccine production has had a rocky start since it began operations March 31, but vaccines play a small role in the company's overall domestic sales, so impact is expected to be negligible
Daiichi Sankyo Withdraws Shipment Of Half The Company's Entire Influenza Vaccine Supply
TOKYO - Daiichi Sankyo Co. Ltd. will trash nearly half of its annual influenza vaccines after tests revealed batches were contaminated by avian reovirus. The company's joint venture with Kitasato Institute for vaccine production has had a rocky start since it began operations March 31, but vaccines play a small role in the company's overall domestic sales, so impact is expected to be negligible
Angels Angle In Biotech
Biotechnology hasn't traditionally been an area of great interest to angel investors, the well-off individuals who invest only their own money in startups.